Results 281 to 290 of about 144,142 (399)

Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options

open access: yesHemaSphere, Volume 9, Issue 12, December 2025.
ABSTRACT Atypical chronic myeloid leukemia (aCML) is a rare form of myelodysplastic (MDS)/myeloproliferative neoplasm (MPN) overlap disorder characterized by neutrophilic leukocytosis with circulating immature myeloid cells (IMC), frequent hepatosplenomegaly, and poor prognosis with high rates of leukemic transformation.
Alessandra Iurlo   +3 more
wiley   +1 more source

Translocation t(5;16)(q32;p13) and Trisomy 8 in an Infant Patient Presenting as Acute Myeloid Leukemia with Eosinophilia

open access: gold, 2015
Ximena Montenegro Garreaud   +4 more
openalex   +1 more source

Allopurinol‐Induced Lymphadenopathy: A Case Report

open access: yes
ACR Open Rheumatology, Volume 7, Issue 12, December 2025.
Mikako Harata, Aparna Das
wiley   +1 more source

A Proof‐of‐Concept Phase 2a Partly Randomised Study Evaluating Leronlimab in Patients With Presumed Non‐Cirrhotic Metabolic Dysfunction–Associated Steatohepatitis

open access: yesLiver International Communications, Volume 6, Issue 4, December 2025.
ABSTRACT Chemokine receptor type 5 (CCR5) is upregulated in the livers of patients with metabolic dysfunction–associated steatohepatitis (MASH). Leronlimab, a humanised IgG4κ monoclonal antibody, directly binds the extracellular domains of CCR5, modulates downstream signalling and potentially can slow, reverse or prevent fibrosis. The aim of this study
Melissa Palmer   +10 more
wiley   +1 more source

High Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy

open access: yesLaryngoscope Investigative Otolaryngology, Volume 10, Issue 6, December 2025.
ABSTRACT Objective This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT,
Seiichiro Kamimura   +4 more
wiley   +1 more source

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

open access: yesMed Research, Volume 1, Issue 3, Page 322-358, December 2025.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy